Branch Retinal Vein Occlusion Clinical Trials 2022

Browse 10 Branch Retinal Vein Occlusion Medical Studies Across 123 Cities

5 Phase 3 Trial · 232 Branch Retinal Vein Occlusion Clinics

Reviewed by Michael Gill, B. Sc.
Photo of texas 1
Phase-Based Progress Estimates
3
Effectiveness
3
Safety

Ozurdex Armfor Macular Edema

McAllen, TX
18+
All Sexes
CRVO occurs when the vessels in the back of the eye become blocked. This creates a dangerous condition because the vessels are weak and prone to leakage. This results in the development of macular edema. Previous studies have shown that inflammatory mediators and growth factors, such as vascular endothelial growth factor (VEGF), are elevated in patients with macular edema associated with CRVO. Ozurdex® is approved by the Food and Drug Administration (FDA) and is available by prescription for macular edema following CRVO and branch retinal vein occlusion (BRVO). It is also indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye. The approved dosage is 0.7 mg. Ranibizumab (Lucentis®) is approved by the Food and Drug Administration (FDA) and is available by prescription for other eye disorders, such as wet age-related macular degeneration (AMD), macular edema following CRVO or BRVO, and diabetic macular edema (DME). The approved dosage for wet AMD and macular edema following CRVO/BROV is 0.5 mg given monthly. The approved dosage for DME is 0.3 mg given monthly. Dr. Gonzalez is conducting an investigational study on the safety and effectiveness of treating CRVO-associated Macular Edema with a combination of 0.7 mg of Ozurdex® and 0.5 mg Lucentis®, given as separate injections into the eye.
Phase 4
Waitlist Available
10 Branch Retinal Vein Occlusion Clinical Trials Near Me
Springfield, IL
Hagerstown, MD
Chambersburg, PA
Tallahassee, FL
More Trial Locations
An interactive map to display trial locations for Clinical Site, Southern Vitreoretinal Assoc, University Retina and Macula Associates, PC, Retina-Vitreous Associates Medical Group, and 148 more locations.
Top Hospitals for Branch Retinal Vein Occlusion Clinical Trials
Location
Active Branch Retinal Vein Occlusion Clinical Trials
All Time Trials for Branch Retinal Vein Occlusion
First Recorded Branch Retinal Vein Occlusion Trial
Trials
Retina Group of New England, Waterford, Connecticut
3
3
2020
Top Treatments for Branch Retinal Vein Occlusion Clinical Trials
Treatment Name
Active Branch Retinal Vein Occlusion Clinical Trials
All Time Trials for Branch Retinal Vein Occlusion
First Recorded Branch Retinal Vein Occlusion Trial
Trials
MB-102 and Zeiss FF450 fundus camera
1
1
2022
Top Cities for Branch Retinal Vein Occlusion Clinical Trials
City
Active Branch Retinal Vein Occlusion Clinical Trials
Top Active Site for Branch Retinal Vein Occlusion Clinical Trials
Trial List
Austin, Texas
9
Retina Research Center
Edina, Minnesota
5
Vitreoretinal Surgery
Hagerstown, Maryland
4
Cumberland Valley Retina PC
Beverly Hills, California
4
Retina-Vitreous Associates Medical Group
Which phases are most popular for branch retinal vein occlusion clinical trials?
How many branch retinal vein occlusion clinical trials are open to youth and / or seniors?
Age Group
Active Branch Retinal Vein Occlusion Clinical Trials
Trial List
Most Recent Branch Retinal Vein Occlusion Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Phase 3 Branch Retinal Vein Occlusion Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
8/1/2007
Phase 3
Senior Friendly Branch Retinal Vein Occlusion Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Recently Completed Studies with FDA Approved Treatments for Branch Retinal Vein Occlusion
Treatment
Year
Mechanism of Action
Sponsor
Active Branch Retinal Vein Occlusion Clinical Trials
MHU650
2020
Novartis Pharmaceuticals
0
Minocycline
2012
Minocycline
National Eye Institute (NEI)
0

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: September 13th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.